Long-term clinical outcome of patients with diabetes and chronic total occlusion underwent drug-eluting stents implantation
10.3760/cma.j.issn.0253-3758.2009.12.009
- VernacularTitle:糖尿病合并冠状动脉慢性完全闭塞性病变患者置入药物洗脱支架的远期预后
- Author:
Han-Jun PEI
1
;
Yong-Jian WU
;
Yue-Jin YANG
;
Ji-Lin CHEN
;
Shu-Bin QIAO
;
Bo XU
;
Jian-Jun LI
;
Jue CHEN
;
Guang-Yuan SONG
;
Zhen-Yan ZHAO
;
Xi-Mei WANG
;
Run-Lin GAO
Author Information
1. 包头医学院附属第一医院
- Keywords:
Arteriosclerosis obliterans;
Diabetes mellitus;
Stents
- From:
Chinese Journal of Cardiology
2009;37(12):1093-1096
- CountryChina
- Language:Chinese
-
Abstract:
Objective The aim of this study was to assess the long-term clinical outcome of patients with diabetes mellitus and chronic total occlusion ( CTO) underwent drug-eluting stents ( DES) implantation. Methods Data of 143 consecutive eligible patients from January, 2006 to May, 2007 were retrospectively analyzed. The endpoint of the study was the major adverse cardiac events ( MACE) , including death, myocardial infarction, target lesion revascularization. The patients were divided into two groups, event group and non-event group, according to the result of follow-up. Results Long-term follow-up was finished in 139 (97.2% ) patients. Mean follow-up duration was (19. 8 ±5. 1) months. MACE rate was 10.5% during follow-up: 3 deaths, 1 myocardial infarction and 11 repeated target lesion revascularization with PCI. Compared with the non-event group, the percentage of residual lesion [(17. 7 ± 1.8)% vs. (15. 4±5. 0)% ,P =0. 001] was significantly higher in the event group, however, the final minimal luminal diameter [(2. 14 ±0. 22)% vs. (2. 89 ±0. 37)% ,P = 0. 004] was lower. Cox regression analysis showed that final luminal diameter (OR; 0.097, 95% Cl; 0. 013-0. 694, P = 0.020) was the only dependant predictor at follow-up. Conclusion Final minimal luminal diameter is an independent predictor of MACE during follow-up for patients with diabetes and CTO underwent DES implantation.
